



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/071,032	02/08/2002	1614	1424	A0000425-01-CFP		30	9

Claude F. Purchase, Jr.
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105



CONFIRMATION NO. 3659

UPDATED FILING RECEIPT



OC00000008843530

Date Mailed: 09/24/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Richard Dennis Dyer, Ann Arbor, MI;
William Glen Harter, Chelsea, MI;
James Lester Hicks, Chelsea, MI;
Adam Richard Johnson, Ann Arbor, MI;
Jie Jack Li, Ann Arbor, MI;
William Howard Roark, Ann Arbor, MI;
Kevon Ray Shuler, Chelsea, MI;

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

RECEIVED

APR 28 2003

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/268,780 02/14/2001

Foreign Applications**Projected Publication Date:** None, application placed under Secrecy Order.**Non-Publication Request:** No**Early Publication Request:** No**Title**

RECEIVED

APR 23 2003

OFFICE OF PETITIONS

USSN: 10/071,032 Filed: February 8, 2002
Inventors: Dyer, et al
"Exhibit A"

Bicyclic pyrimidine matrix metalloproteinase inhibitors

Preliminary Class

514

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

RECEIVED

APR 2 3 2003

OFFICE OF PETITIONS



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/071,032	02/08/02	DYER, ET AL.	A0000425-01-CFP

CLAUDE F. PURCHASE, JR.
WARNER-LAMBERT COMPANY
2800 PLYMOUTH ROAD
ANN ARBOR, MI 48105

RECEIVED

APR 28 2003

TECH CENTER 1600/2900

EXAMINER	
ART UNIT	PAPER NUMBER
3	

APR 23 2003 DATE MAILED:
26 JUN 2002

OFFICE OF PETITIONS

**IF NO RESPONSE TO THIS NOTICE IS RECEIVED WITHIN FORTY-FIVE DAYS, A
FORMAL REQUIREMENT WILL BE ISSUED**

The subject matter of this application appears to:

- be "useful in the production or utilization of special nuclear material or atomic energy" as recited in 42 U.S.C. 2182 (Department of Energy (DOE)).
- "have significant utility in the conduct of aeronautical and space activities" as recited in 42 U.S.C. 2457 (National Aeronautics and Space Administration (NASA)).

Accordingly, no patent can issue on this application unless applicant(s) file a statement (under oath or in the form of a declaration as provided by 37 CFR 1.68) setting forth (1) the full facts concerning the circumstances under which the invention was made and conceived and (2) the relationship (if any) of the invention to the performance of any work under any contract or other arrangement with the Agency(ies) noted above. On the reverse side of this form is an example of an acceptable format for this statement. The language appearing in paragraphs III and/or IV of the example *must* appear if applicant is attempting to establish that no relationship (under item 2 above) exists.

If the invention disclosed in this application was developed under a contract, grant or cooperative agreement between the Agency indicated above and a person, small business or non-profit organization and rights to the invention have been determined by specific reference to 35 U.S.C. 202 in the contract, grant or cooperative agreement, then applicant need not submit the statement described above. Instead, applicant may file a verified statement (under oath or in the form of a declaration, 37 CFR 1.68) setting forth the information required by 35 U.S.C. 202(c)(6).

IF NO STATEMENT HAS BEEN RECEIVED WITHIN FORTY-FIVE DAYS OF THE MAIL DATE INDICATED ABOVE, a formal requirement for statement will then be issued. No provision is made for extension of the statutory thirty-day period for response to the formal requirement and the penalty for failure to file an acceptable and timely statement is abandonment of the application. Therefore, applicants are strongly encouraged to submit a statement at this time in order to avoid the issuance of a formal requirement.

IT IS IMPORTANT TO NOTE that the statement must accurately represent the property rights situation of the claimed invention if and when the application is found allowable. Thus, if during prosecution before the examiner, the claimed invention is so altered or the property rights situation so changed as to impact the accuracy of a statement submitted earlier, a supplemental statement must be filed. Failure to submit such additional information where appropriate may be considered a false representation of material facts and render the patent owner vulnerable to loss of patent rights and other sanctions as set forth in the statutes. The PTO will not review allowed applications for this possibility. The responsibility for complying with the statutes rests with the applicants.

Any questions regarding this requirement should be directed to Licensing and Review at (703) 306-4191.

**PLEASE DIRECT ALL COMMUNICATIONS RELATING TO THIS MATTER TO THE
ATTENTION OF LICENSING AND REVIEW**

USSN: 10/071,032 Filed: February 8, 2002
Inventors: Dyer, et al "Exhibit B"

The following is an example of an acceptable property rights statement. Statements of this type are, of course, only suitable for situations in which NO Agency funds or other considerations were involved in the making or conception of the invention. While this example is in the form of a declaration, a sworn document is equally acceptable.

I (We) _____

citizens of _____

residing at _____

declare:

That I (we) made and conceived the invention described and claimed in patent application:

Serial Number _____ filed in the United States of America on _____

titled _____

(Check and complete either I or II below)

I. (For Inventors Employed by an Organization) That I (we) made and conceived this invention while employed by _____ . That the invention is related to the work I am (we are) employed to perform and was made within the scope of my (our) employment duties; That the invention was made during working hours and with the use of facilities, equipment, materials, funds, information and services of _____ . Other relevant

facts are _____
(name of employer)

That to the best of my (our) knowledge and belief (and/or) based upon information provided by _____

of _____

—OR—

II. (For Self-Employed Inventors) That I (we) made and conceived this invention on my (our) own time using only my (our) own facilities, equipment, materials, funds, information and services. Other relevant facts are _____

(Check III and/or IV below as appropriate)

That to the best of my (our) knowledge and belief:

III. The invention was not made or conceived in the course of, or in connection with, or under the terms of any contract, subcontract or arrangement entered into with or for the benefit of the United States Atomic Energy Commission or its successors: Energy Research and Development Administration or the Department of Energy.

—AND/OR—

IV. The invention was not made (conceived or first actually reduced to practice) under nor is there any relationship of the invention to the performance of any work under any contract of the National Aeronautics and Space Administration.

The undersigned inventor(s) declare further that all statements made herein of his or her (their) own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Inventor's Signature: _____

Post Office Address: _____

Date: _____

Inventor's Signature: _____

Post Office Address: _____

Date: _____



Duplicate of
paper # 10

RECEIVED
APR 25 2003
A0000425-01-CFR
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : DYER, RICHARD DENNIS ET AL. EXAMINER : Unknown

SERIAL NO : 10/071,032 ART UNIT : 1614

FILED : FEBRUARY 8, 2002 PAPER NO : 4

FOR : BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS

RESPONSE

July 23, 2002

RECEIVED
JUN 17 2003
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231
Attention: Licensing and Review

RECEIVED

MAY 28 2003

GROUP 3600

This letter is responsive to an informal notice dated June 26, 2002 ("Notice"), from Licensing and Review which alleged that the subject matter of the invention in the above-identified application "appears to: 'have significant utility in the conduct of aeronautical and space activities' as recited in 42 U.S.C. 2457 (National Aeronautics and Space Administration (NASA))."

The Notice further alleged that "no patent can issue on this application unless applicant(s) file a statement (under oath or in the form of a declaration as provided by 37 CFR 1.68) setting forth (1) the full facts concerning the circumstances under which the invention was made and conceived and (2) the relationship (if any) of the invention to the performance of any work under any contract or other arrangement with the Agency (ies) noted above.

RECEIVED
APR 23 2003
OFFICE OF PETITIONS

USSN: 10/071,032 Filed: February 8, 2002
"Exhibit C"
Inventors: Dyer, et al

The Notice set a deadline for response of forty-five days from the mailing date of the Notice, which deadline is

August 10, 2002.

As required by the Notice, enclosed herewith as a separate paper is a Declaration under 37 CFR 1.68 ("Declaration") by the Applicants that sets forth (1) the full facts concerning the circumstances under which the invention was made and conceived and (2) the relationship (if any) of the invention to the performance of any work under any contract or other arrangement with the Agency noted above.

In the Declaration, the Applicants declare that the invention was not made (conceived or first actually reduced to practice) under nor is there any relationship of the invention to the performance of any work under any contract of NASA.

The Declaration is hereby incorporated by reference herein.

This paper is deposited with the United States Postal Service as "Express Mail Post Office to Addressee" on the above-recited date of this letter.

In view of Applicants timely submission of the above Declaration, Applicants respectfully request the Commissioner of Patents determine that a patent can issue on this application.

The Commissioner for Patents is hereby authorized to charge any fees required for this communication, or credit any overpayment of fees, to deposit account 23-0455.

The undersigned would welcome a telephone call from the Commissioner to discuss any matters.

Respectfully submitted,

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.

Reg. No. 47,871

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553

Enc. Original of Declaration under 37 CFR 1.68 (2 pages)

RECEIVED

APR 2 3 2003

OFFICE OF PETITIONS



A0000425-01-CFP

DECLARATION

We, Richard Dennis Dyer, William Glen Harter, James Lester Hicks, Adam Richard Johnson, Jie Jack Li, William Howard Roark, and Kevon Ray Shuler, citizens of the United States, residing at the below indicated addresses, declare:

That we made and conceived the invention described and claimed in patent application:

Serial Number 10/071,032, filed in the United States of America on February 8, 2002, titled "Bicyclic Pyrimidine Matrix Metalloproteinase Inhibitors".

- I. (*For Inventors Employed by an Organization*) That we made and conceived this invention while employed by Warner-Lambert Company. That the invention is related to the work we are employed to perform and was made within the scope of our employment duties; That the invention was made during working hours and with the use of facilities, equipment, materials, funds, information and services of Warner-Lambert Company. Other relevant facts are _____ . That to the best of our knowledge and belief (and/or) based upon information provided by _____ of _____.
- II. (*For Self-Employed Inventors*) That I (we) made and conceived this invention on my (our) own time using only my (our) own facilities, equipment, materials, funds, information and services. Other relevant facts are _____ .

That to the best of our knowledge and belief:

- III. The invention was not made or conceived in the course of, or in connection with, or under the terms of any contract, subcontract or arrangement entered into with or for the benefit of the United States Atomic Energy Commission or its successors: Energy Research and Development Administration or the Department of Energy.
- IV. The invention was not made (conceived or first actually reduced to practice) under nor is there any relationship of the invention to the performance of any work under any contract of the National Aeronautics and Space Administration.

The undersigned inventors declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

RECEIVED

JUN 17 2003

TECH CENTER 1600/2900

RECEIVED

APR 23 2003

OFFICE OF PETITIONS

USSN: 10/071,032 Filed: February 8, 2002
Inventors: Dyer, et al "Exhibit D"

Full name of sole or first inventor

RICHARD DENNIS DYER

Sole or first inventor signature



Date

7/15/02

Residence

Ann Arbor, MI 48105

Citizenship

United States

Post Office Address

3436 Gettysburg Road

Ann Arbor, MI 48105

Full name of sole or second inventor

WILLIAM GLEN HARTER

Sole or second inventor signature



Date

7/12/02

Residence

Chelsea, MI 48118

Citizenship

United States

Post Office Address

3750 Shagbark

Chelsea, MI 48118

Full name of sole or third inventor

JAMES LESTER HICKS

Sole or third inventor signature



Date

7/15/2002

Residence

Chelsea, MI 48118

Citizenship

United States

Post Office Address


17830 Garvey Road

Chelsea, MI 48118

Full name of sole or fourth inventor

ADAM RICHARD JOHNSON

Sole or fourth inventor signature



Date

07-12-02

Residence

Ann Arbor, MI 48105

Citizenship

United States

Post Office Address

3544 Greenbrier Road, Apt. 445B

Ann Arbor, MI 48105

RECEIVED

APR 2 3 2003

OFFICE OF PETITIONS

	Full name of sole or fifth inventor JIE JACK LI	Date
	Sole or fifth inventor signature <i>Jie Jack Li</i>	<i>July 15, 2002</i>
	Residence Ann Arbor, MI 48103	
	Citizenship United States	
	Post Office Address 3282 Honeysuckle Drive	
	Ann Arbor, MI 48103	

	Full name of sole or sixth inventor WILLIAM HOWARD ROARK	Date
	Sole or sixth inventor signature <i>William Howard Roark</i>	<i>7/15/2002</i>
	Residence Ann Arbor, MI 48104	
	Citizenship United States	
	Post Office Address 2810 Gladstone Avenue	
	Ann Arbor, MI 48104	

	Full name of sole or seventh inventor KEVON RAY SHULER	Date
	Sole or seventh inventor signature <i>Kevon Ray Shuler</i>	<i>7/23/2002</i>
	Residence Chelsea, MI 48118	
	Citizenship United States	
	Post Office Address 146 E. Summit	
	Chelsea, MI 48118	

RECEIVED
APR 23 2003
OFFICE OF PETITIONS



JAN 13 2003

Please type a plus sign (+) inside this box →

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

	Application Number 10/071,032
	Filing Date February 8, 2002
	First Named Inventor Richard Dennis Dyer
	Group Art Unit 1614
	Examiner Name Unknown
Total Number of Pages in This Submission	Attorney Docket Number A0000425-01-CFP

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)
<small>Remarks</small>		
<small>Declaration of Inventors Copy of USPTO Notice Certificate of Express Mail Return Postcard</small>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Claude F. Purchase, Jr.
Signature	
Date	7/23/02

RECEIVED
APR 25 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 7/23/02			
--	--	--	--

Type or printed name Nancy Dermbach

Signature Date 7/23/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 23 2003

OFFICE OF PETITIONS

REC
JUN 17 2003
TECH CENTER 1600/2900


CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s):

Docket No.
A0000425-01-CFPSerial No.
10/071,032Filing Date
8-Feb-2002Examiner
UnknownGroup Art
1614

Invention:

BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS



I hereby certify that this

Response to United States Patent and Trademark Office

(Identify type of correspondence)

Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

on July 23, 2002

(Date)

Nancy Dembach

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

EU446351675US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

RECEIVED
JUN 17 2003
TECH CENTER 1600/2900

(625)
JPM
U.S. Patent and Trademark Office
Washington, D.C.
20591-0002

THE UNITED STATES PATENT AND TRADEMARK OFFICE IS IN RECEIPT OF THE FOLLOWING:


1. TRANSMITTAL FORM (1 PAGE)
2. RESPONSE TO USPTO NOTICE (3 PAGES)
3. DECLARATION OF INVENTORS (3 PAGES)
4. COPY OF USPTO NOTICE (1 PAGE)
5. CERTIFICATE OF EXPRESS MAILING - NO. EU446351675US
6. AUTH. TO DEBIT/CREDIT DEPOSIT ACCOUNT 23-0495
7. RETURN POSTCARD

INVENTORS: RICHARD DENNIS DYER, ET AL


INVENTION TITLED: "BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS"

USSN: 10/071,032 FILED: 02/8/02

CFP:NDD
JULY 23, 2002
A0000425-01-CFP✓



USSN: 10/071,032 Filed: February 8, 2002
Inventors: Dyer, et al "Exhibit G"



**Warner-Lambert Company
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105**



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
60/268,780	02/14/2001	150		A0000425L1-01GACFF			

Charles W. Ashbrook
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48103

RECEIVED

JUN 07 2001

A/A PATENT DEPT.

CONFIRMATION NO. 1867

FILING RECEIPT



OC00000006137984

Date Mailed: 06/04/2001

Receipt is acknowledged of this provisional Patent Application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Richard Dennis Dyer, Ann Arbor, MI;
James Lester Hicks, Chelsea, MI;
Adam Richard Johnson, Ann Arbor, MI;
Jie Jack Li, Ann Arbor, MI;
William Howard Roark, Ann Arbor, MI;

If Required, Foreign Filing License Granted 06/01/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

Bicyclic pyrimidine matrix metalloproteinase inhibitors

Data entry by : SOUNANNARATH, LINDA

Team : OIPE

Date: 06/04/2001

USSN: 10/071,032 Filed: February 8, 2002
Inventors: Dyer, et al "Exhibit H"

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231